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One in five pregnant women is obese in the UK. Obesity in pregnancy is associated 
with risks of complications for the mother and child. Mechanisms linking maternal 
obesity with adverse outcomes for the offspring are not entirely understood though 
recent studies have suggested epigenetic modifications may be important. As the 
placenta plays a key role in fetal nutrition, metabolism and protection we 
hypothesized that there would be DNA methylation changes between lean and obese 
placenta. DNA methylation array (Infinium HD Assay) was carried out on placentas 
collected from n=31 obese (BMI>40 kg/m2) and n=29 lean (BMI<25 kg/m2) women. 
Three genes miR-411, HSD17B4 and FABP1, with false discovery rate (FDR) 
adjusted P<0.05, and potentially relevant to maternal obesity, gestational diabetes or 
fat metabolism after literature review, were selected for validation of DNA 
methylation by pyrosequencing and measurement of mRNA levels by RT-qPCR. The 
mean (sd) miR-411 and FABP1 DNA methylation percentage was significantly 
higher in obese placenta vs lean group (68.9 (13.4)% vs 58.9 (15.8)%, P=0.01 and 
89.7(2.76)% vs 85.8(7.16)%, P=0.01, respectively), in accord with the array findings. 
There were no differences in HSD17B4 DNA methylation between groups. MiR-411 
DNA methylation was significantly higher in samples from non-smoking obese vs 
non-smoking lean (70.42(9.6)% vs 58.63(17.4)%, P=0.02). MiR-411 DNA 
methylation percentage was highest in placentas from male babies born to obese 
	 4	
mothers. There were no significant differences in mRNA levels of miR-411 between 
obese and lean groups and there were no correlations between methylation levels and 
mRNA levels of miR-411 in either obese or lean placentas (miR-411 obese r=0.21, 
P=0.32; lean r=-0.32, P=0.14). MiR-411 mRNA levels were significantly higher in 
current smokers vs non-smokers and ex-smokers (3.61(3.2) vs 1.3(1.2) vs 1.13(0.7), 
P≤0.05) in all placenta samples. Infant BMI was also positively correlated with 
mRNA levels of miR-411 in lean but not obese group (lean r=0.636, P=0.003; obese 
r=0.021, P=0.931). Maternal age was negatively correlated with miR-411 mRNA 
levels in obese placenta (r= -0.42, P=0.05). We were unable to detect FABP1 mRNA 
in either lean or obese placenta. Hence, we conclude that there are differences of 
DNA methylation and gene expression between lean and obese placenta, and these 
differences are also influenced by maternal environment, fetal sex and infant BMI. 
The explanation for the lack of association of DNA methylation changes and gene 
expression changes is not known but may be due to the small magnitude of the DNA 
methylation changes. Further studies are needed to understand the functional 
outcomes of these DNA methylation changes. Exploration of the regulation pathway, 




One in five pregnant women is obese in the UK. Obesity in pregnancy is known to be 
harmful for the health of both mother and child. It is still not clear why and how the 
body weight of mothers could influence the health of their babies. Recent studies 
have suggested that DNA methylation might be important. DNA methylation is a 
process which regulates the way genes are turned “on” and “off”. As the placenta 
plays a key role in fetal nutrition, metabolism and protection, we hypothesized that 
DNA methylation would be different in the placentas from normal weight compared 
with obese pregnant women. We measured the DNA methylation in 60 placentas (31 
from obese mothers, 29 from normal weight mothers), and identified three genes 
(miR-411, HSD17B4 and FABP1) for validation in the top list of DNA methylation 
changes in this panel. Existing literature shows all these three genes are potentially 
relevant to maternal obesity, diabetes during pregnancy or fat metabolism. After 
analyzing the gene expression and DNA methylation, we found the DNA methylation 
changes in miR-411 and FABP1 were higher in the placentas from the obese mothers 
compared to the normal weight mothers. We could not replicate the findings of 
differences in HSD17B4 DNA methylation between groups. Intriguingly we found 
no correlation between DNA methylation changes and gene expression. However, we 
showed that there were other factors that were associated with changes in either DNA 
methylation or expression of these genes. For example, mothers who were smoking 
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during pregnancy had more changes in gene miR-411 expression than those mothers 
who quit smoking before pregnancy or who had never smoked. We also found that 
the baby boys who were born from obese mothers had the highest miR-411 DNA 
methylation changes. Furthermore the changes in miR-411 gene expression were 
linked to the baby BMI. We conclude that DNA methylation is different in placentas 
from obese and normal weight mothers. We showed that maternal smoking and baby 
sex can influence both the DNA methylation and gene expression in placentas. 
Though we found no links between DNA methylation and gene expression, this 
might because of mother behaviours, such as smoking, and baby sex, etc. In future 
studies we plan to investigate whether these DNA methylation changes influence the 
health of the baby. In addition, our work has highlighted that miR-411 could be a 
novel gene to investigate further and understand it’s role in transmitting the adverse 
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1 Introduction  
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1.1 Obese pregnant women 
The prevalence of obesity, defined as a body mass index (BMI) 30 kg/m2 or greater, 
among the general population is increasing worldwide. In the UK, one in five women 
are obese during pregnancy (Heslehurst et al., 2010). This epidemic has raised 
concern due to the increasing risk of adverse maternal and fetal health outcomes. 
Obese pregnant women face a high risk of pregnancy complications, such as 
hypertension, gestational diabetes and miscarriage (Gaillard et al., 2011; Leng et al., 
2015), and their offspring are exposed to increased risk of macrosomia, large for 
gestational age (LGA) infants and still birth (Ehrenberg, Mercer and Catalano, 2004; 
Kristensen et al., 2005; Heude et al., 2012). In the Developmental Origins of Health 
and Disease (DOHaD) hypothesis, the key role of environmental exposures during 
prenatal and perinatal periods on the adverse children later health and development, 
including increased risk of cardiovascular and metabolic diseases (Gluckman and 
Hanson, 2006) is described. The hypothesis has been extended to include 
environmental exposures such as obesity. Thus maternal overweight and over 
nutrition have been associated with fetal adiposity, metabolic changes in the 
offspring including type 2 diabetes (Lake, Power and Cole, 1997; Dabelea et al., 
2000) and increased branched-chain amino acid (BCAA), which is positively 
associated with central adiposity (Perng et al., 2014), as well as increased risk of 
cardiovascular disease and premature mortality (Reynolds et al., 2013; Eriksson et 
al., 2014). Fetal programming may also be influenced by environmental stress 
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factors, such as maternal depression, anxiety, dietary habits/obesity and smoking 
(Smedts et al., 2009; Joubert et al., 2012), which may have long-lasting health 
influences on the offspring (Bird, 2002).  
	
1.2 Placental function during obese pregnancy 
The placenta is a unique connection between the mother and fetus and has 
multiple-functions in this relationship. The placenta offers nutrition, transfers oxygen 
to maintain the growth of fetus by exchange blood from the mother to the fetal side, 
and it also transports waste and carbon dioxide that come from the fetus. The 
placenta also plays a key role in the fetal immune system by passing IgG antibodies 
to the fetus (Simister, 2003). Another important function of the placenta is endocrine. 
During pregnancy, the placenta releases hormones which are vital for fetal growth, 
such as the human chorionic gonadotropin (hCG) hormone; Progesterone is 
important for embryo implantation and offers protection from spontaneous abortion 
(Hassan et al., 2011); Estrogen is also crucial for fetal growth by mediating the 
development of breast, playing an important role in breastfeeding and fetal health 
(Brisken and O’Malley, 2010). 
 
The placenta is such an important organ during normal implantation: the 
cytotrophoblast cells invade the maternal surface, and transform maternal smooth 
muscle and decidual vascular endothelial cells to form endovascular cytotrophoblast, 
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while the endovascular cytotrophoblast cells form high-caliber capacitance vessels 
allow maternal transferring oxygen and nutrients to fetus through placenta (Damsky, 
Fitzgerald and Fisher, 1992). These transferring pathways are influenced by the 
thickness of the placenta membrane and the number of transporters in the trophoblast 
membrane. During normal pregnancy, both expansion of the placenta membrane and 
reduction in thickness of the interhaemal membrane were observed in human and in a 
mouse model (Coan, Ferguson-Smith and Burton, 2004; Mayhew, 2008). Apart from 
the morphology changes during normal pregnancy, the changes of levels of 
hormones in the maternal and fetal circulations were also demonstrated in early 
studies. The syncytiotrophoblast secretes a variety of hormones and growth factors to 
help maintain the normal function of placenta and the communication between 
maternal and fetal during pregnancy. For example, estrone is secreted from maternal 
ovaries or adrenal in early pregnancy. Placenta later starts to secrete estrone which is 
sourced from maternal circulation and the concentration of estrone is continually 
increased until the late stage of gestation (Tulchinsky and Hobel, 1973; Lindberg, 
Nilsson and Johansson, 1974). 
 
Therefore, the placenta is crucial to normal pregnancy and fetal development. 
Dysfunction of placenta with different pregnant complications (diabetes, 
preeclampsia and obesity, etc.) and the association with fetal outcome has been 
	 18	
discussed in many studies (Baschat and Hecher, 2004; La Torre et al., 2006; Van den 
Bergh et al., 2008). 
 
In this study, we mainly focus on the changes that happen in obese placenta. 
Dysfunction of placenta in women with obesity and the association with fetal 
development has been discussed in a number of studies. The placenta is a major 
source of cytokines during pregnancy (Bowen et al., 2002), tumor necrosis factor 
alpha (TNFα) is secreted to both mother and fetus. During placental inflammatory 
disorders, such as under obese pregnant conditions (Challier et al., 2008; Du et al., 
2010), inflammation was suggested to be a reason contributing to adverse fetal 
development, such as preterm birth and neonatal brain damage, with associated fetal 
and neonatal morbidity (Redline, 2004). Moreover, some inflammatory mediators, 
mRNA levels of inflammation relevant cytokines including interleukin-8 (IL-8), 
monocyte chemoattractant protein 1 (MCP-1) and Chemokine (C-X-C Motif) 
Receptor 2 (CXCR2) were higher in the placenta of obese pregnant women than lean 
pregnant women, and higher IL-6 levels were also found in the maternal circulation 
with obesity compared with lean women (Roberts et al., 2011), suggesting that 
obesity is associated with increased inflammation during pregnancy. In another study, 
an increase in macrophages and pro-inflammatory mediators were reported in the 
placenta of overweight pregnant women compared to normal weight women 
	 19	
(Challier et al., 2008). Apart from obesity induced placental inflammation, 
morphological changes in placenta from obese women were also described in a few 
studies. The activity of mitochondria was lower in obese placenta as well as the 
decreased mitochondrial DNA (mtDNA content), while the mitochondrial oxidative 
stress, which was measured by mitochondrial hydrogen peroxide (H2O2) levels, was 
increased in the obese placenta compared with non-obese placenta (Hastie and 
Lappas, 2014). The authors suggested that these changes in mitochondria will 
increase the level of reactive oxygen species (ROS). The production of ROS is 
involved in embryo implantation and development, so any changes in ROS could 
lead to altered fetal growth (Lappas, 2014). A recent study which recruited 234 
pregnant women, demonstrated the transporters of placental mitochondrial 
cholesterol and the mitochondrial translocator protein (TSPO) were significantly 
decreased in pregnant women with obesity. The study demonstrated that cholesterol 
plays a main role in estrogen and progesterone synthesis in placenta and TSPO is the 
cholesterol binding protein; thus their study suggested the changes of mitochondrial 
cholesterol will largely influence placental function and pregnancy losses (Lassance 
et al., 2016). In a study from Hayward et al., in which chorionic plate arteries (CPAs) 
were pre-constricted followed by sodium nitroprusside (SNP, a vasodilator) treatment, 
the vasodilation in CPAs was decreased in overweight pregnant women. This would 
potentially influence the transportation of oxygen and nutrition between mother and 
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fetus (Hayward et al., 2013).	 Another study reported that placental villous 
proliferation and apoptosis had a positive association with maternal weight. Changes 
in placenta size and integrity of the placental barrier will potentially influence the 
transfer of nutrition and oxygen between maternal and fetus, and those changes could 
influence pregnancy outcomes (Higgins et al., 2013). In terms of the influence of 
placental dysfunction on nutrition transport, one study demonstrated obese pregnant 
women had lower circulating levels of iron but the placental transferrin receptor 
(pTFR1) expression in placenta was higher than lean pregnant women, which 
indicates that placenta could protect itself by adaption to the potential adverse fetal 
environment which is associated with obesity (Garcia-Valdes et al., 2015). In another 
study, a decreased expression of insulin-regulated glucose transporter 4 (GLUT4) 
mRNA in obese placenta was described. They found the dysregulation of GLUT4 
could result in increased levels of circulating free glucose, which implies obesity 
during pregnancy may have impact on the insulin signaling pathway. The influence 
of GLUT4 and phosphatidylinositol 3-kinase (PI3K) on glucose taken to cell 
membrane could induce gestational diabetes (Colomiere et al., 2009). There are some 
studies suggesting that the placental responses to maternal weight are fetal sex 
dependent. To be more specific, Brass et al. (2013) carried out a study using human 
placentas and showed that female offspring could uptake a higher placental 
monounsaturated fat, oleic acid (OA), which was studied as a biomarker of 
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cardiovascular disease (Schwingshackl, Strasser and Hoffmann, 2011). In obese 
mothers male offspring showed lower placental oleic acid uptake, which suggested 
that the male fetus is more vulnerable than the female fetus under the environment 
of maternal obesity (Brass et al., 2013). From the studies mentioned above, we 
could conclude that the placenta might play a protective role on fetal growth 
during pregnancy from maternal different conditions and the function of placenta 
could be influenced by pregnancy environment and different fetal status too. 
 
1.3 Epigenetic modification and DNA methylation 
Epigenetic modification is defined as a key pathway to regulate gene expression 
stabilization. The definition of “epigenetic” was first mentioned by Waddington 
(Waddington, 1956), and has been defined as ‘the inheritable changes in gene 
expression due to the influence of environment factors and without changes of DNA 
sequence’ (Jablonka and Lamb, 2006). 
The mechanisms of epigenetic modification include DNA methylation, histone 
modification and non-coding RNAs (Figure 1). DNA methylation is one of the 
common epigenetic mechanisms and has been most studied in the context of fetal 
developmental programing (Waterland and Jirtle, 2004; Gentilini et al., 2013). The 
process of DNA methylation is the addition of a methyl group to the 5’carbon of 
cytosines, mainly in the context of cytosine-guanine dinucleotides, a process which is 
catalyzed by the DNA methyltransferases (DNMTs) and this largely results in the 
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repression of gene transcription. Groups of unmethylated CpGs are named as ‘CpG 
islands’, which are mainly located in promoters and at the 5’ end of genes. 
Methylation in the ‘CpG islands’ is highly relevant to gene inactivity (Godfrey, 
Costello and Lillycrop, 2015). DNA methylation is observed in most mammals, 
including human, mouse and sheep (Santos et al., 2002; Beaujean et al., 2004; 
Joubert et al., 2012). DNA methylation also occurs in specific tissues, for example, 
embryonic stem cells, germ cells and trophoblast stem cells. Those cells all have 
their own unique DNA methylation patterns (Ohgane, Yagi and Shiota, 2008). 
Moreover, DNA methylation is associated with imprinted gene and X chromosome 
inactivation (Jones and Takai, 2001). Thus, analyzing DNA methylation is an 








Figure 1. The process of epigenetic modification. DNA methylation: methylated sites 
on the gene could influence the activity the gene. Histone modification: the 
epigenetic factors binding on histone “tails” could change the activity of the DNA 
wrapping on the histone. 
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1.3.1 Epigenetic modifications in obese pregnancy 
A number of studies have started to investigate whether epigenetic modifications 
may occur during obese pregnancy though whether these are linked to adverse 
offspring outcomes is still unclear. Different types of samples were used in the 
studies comparing DNA methylation expressions between obese and lean pregnant 
women. A summary of the available literature about DNA methylation between lean 
and obese pregnant women is shown in Table 1. 
 
In total, five studies investigated differences in individual genes’ methylation 
according to maternal obesity by using umbilical cord blood. Another five studies 
analyzed global gene methylation by using umbilical cord blood and one study using 
maternal visceral and abdominal fat tissues. The variables of maternal weight, BMI, 
Gestational weight gain (GWG), maternal glucose and birth weight have all been 
analyzed in these studies to test whether they are associated with DNA methylation 
differences in placenta and offspring. 
Umbilical cord blood is one of the most common tissue samples used in DNA 
methylation studies, as cord blood can be immediately and easily collected after birth. 
Promoter methylation of the proliferator- activated receptor-γ co-activator 1α gene 
(PPARGC1A) which is relevant to gluconeogenesis (a process to generate glucose 
from non-carbohydrate carbon substrates), was found positively corresponding with 
maternal BMI in a study with 88 healthy pregnant women (Gemma et al., 2009). 
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However, in another study, which recruited pregnant women with GDM (gestational 
diabetes mellitus), PPARGC1A promoter methylation in cord blood was found 
negatively associated with maternal glucose concentration and obesity (Xie et al., 
2015). Insulin-like growth factor 2 (IGF-2) DNA methylation was reported as 
decreased in obese cord blood, whereas aryl-hydrocarbon receptor repressor (AHRR) 
was increased in obese pregnant women (Hoyo et al., 2012; Burris et al., 2015). No 
association of LINE-1 (Long Interspersed Element-1) methylation was found with 
BMI in both cord blood and placenta, but the methylation of LINE-1 was lower in 
low birth weight/ high birth weight fetus (Michels, Harris and Barault, 2011). Other 
studies have demonstrated the changes of global DNA methylation in obese pregnant 
women compared with lean pregnant women. GWG showed no association with 
global DNA methylation while maternal underweight was positively linked with fetal 
DNA methylation and there was no differences of CpG sites methylation in between 
overweight and normal pregnant women (Sharp et al., 2015). Greater GWG was also 
described with increasing DNA methylation in CpG sites in gene matrix 
metalloproteinase-7 (MMP7) and Nuclear factor NF- kappa -B p105 subunit (NFKB1) 
etc. (Morales et al., 2014). A similar study carried out by Herbstman et al. using 
umbilical cord blood, also supports the view that BMI was negatively associated with 
global DNA methylation (Herbstman et al., 2013). By contrast, another study 
demonstrated increasing BMI was associated with high levels of fetal DNA 
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methylation as well as birth weight (Liu et al., 2014).  IGF2 differentially methylated 
regions (DMR) – such as H19 DMR, was found increasing with maternal weight 
(Soubry et al., 2013). 
Visceral and abdominal fat tissues were also used in one study to analyze the 
differences of DNA methylation between lean and obese pregnant women. In one 
study, DNA methylation of indolethylamine N-methyltransferase (INMT) and Ephrin 
type-B receptor 6 (EPHB6) were lower in obese group compared with lean pregnant 
women (Bashiri et al., 2014). There are three papers demonstrating DNA methylation 
in the placenta. One study demonstrated a positive association of PPARGC1A DNA 
methylation levels in placenta with maternal glucose level (Côté et al., 2016), which 
is consistent with the study performed by Xie et al. (2015). Whether there was a 
correlation of DNA methylation with maternal BMI and infant birth weight was not 
tested in either study. In another study, there was no association between placenta 
DNA methylation and maternal BMI (Michels, Harris and Barault, 2011). The reason 
for those differences in maternal BMI with PPARGC1A DNA methylation might due 
to different samples tested in each study (umbilical cord vs placenta), suggesting the 
possibility that DNA methylation can be varied from different tissues. Another 
reason is different demographic characteristic of the women from which the samples 


















































































































































Therefore, epigenetic modification is a potential mechanism to investigate the 
association between maternal obesity and development of disease in childhood and 
adult life. In this study, we used placenta as a target tissue to analyze whether there 
are differences in DNA methylation between lean and obese women, as few studies 
in the literature have focused on the analysis of placenta tissues in lean and obese 
groups and only a few studies have big sample sizes. 
 
1.4 Aim and hypothesis 
The aim of this study was to investigate whether there are differences in DNA 
methylation in obese and lean placenta by using a DNA methylation array and by 
validating key genes found to be different between lean and obese by pyrosequencing. 
The hypothesis was that there would be higher DNA methylation in obese placenta 








2 Materials and Methods  
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2.1 Samples and recruitment 
Placenta samples for DNA extraction were from a prospective cohort study of very 
severely obese (SO) pregnant women in Edinburgh, Scotland, UK (Mina et al., 
2015a). Briefly, pregnant women were defined as lean (BMI≤25 kg/m 2) and SO 
(BMI≥40 kg/m 2) women at antenatal booking. Lean pregnant women with singleton 
pregnancies were recruited from community antenatal clinics and SO pregnant 
women with singleton pregnancies were recruited from a specialist antenatal 
metabolic clinic (Mina et al., 2015a). Ethical approval and written informed consent 
were obtained (references 08/S1101/39 and 13/ES/0126). In a previous study using 
placental samples from this cohort it has been demonstrated that maternal distress 
was associated with changes in placental mRNA genes regulating fetal 
glucocorticoid exposure, with sex-specific differences such that female fetuses were 
more vulnerable to glucocorticoid exposure (Mina et al., 2015b). 
 
A total number of 93 placental samples (43 lean and 50 obese) were selected from 
the Edinburgh Reproductive Tissue Bio-Bank (ERTBB). Women with gestational 
diabetes, treated with antenatal steroids during pregnancy and preterm birth (< 36 
weeks) were excluded. From these, we analyzed data from 60 placental samples 
(exclude missing data in maternal weight/BMI and bad quality samples from RNA 
extraction) with lean (n=29) and obese (n=30) pregnant women samples. Five 
samples were excluded from the sample pool as we found the records of those 
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samples in ERTBB, such as birth weight, were not matched with the record from the 
hospital.  
 
2.2 Placenta collection and DNA extraction from placenta tissues 
Human placenta samples were collected from ERTBB as detailed in Mina et al 
(2015b). Placental tissues were collected from the center side of the placenta and 
were stored in RNAlater solution (Qiagen, Manchester, UK) at 4 ◦C for 24 h and 
subsequently frozen at −80 ◦C.  
 
We applied the QIAamp® DNA Mini Kit (Qiagen, Crawley, West Sussex, UK) 
protocol for DNA isolation from fibrous tissues. Approximately 30 mg placenta 
tissue was cut and added to a 1.5 ml microcentrifuge tube with 180 µl lysis buffer 
ATL and 20 µl proteinase K mixture. The tube was next incubated in a rotating air 
incubator at 56 ◦C overnight to ensure complete tissue lysis. On the following day 
RNase A (4 µl, 100 mg/ml; Qiagen, Crawley, West Sussex, UK) and buffer AL (175 
µl) were added to each sample for homogenized and the mixtures were incubated at 
70 ◦C for 10 minutes. Samples were subsequently transferred to another set of clear 
tubes and mixed with 100% ethanol (200 µl) followed by a quick spin at 6000 xg for 
2 minutes. Samples were then transferred to the QIAamp Mini spin column, and 
washed with buffer AW1 and AW2 as per the manufacturer’s handbook and the final 
DNA samples were eluted in 150 µl of elution buffer AE. 
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2.3 DNA qualification and verification of integrity 
The concentration and quality of isolated DNA were evaluated using the Nanodrop 
(Thermo-Scientific, Loughborough, UK) and the reading of 260/280 and 260/230 
ratio. A good quality of DNA is generally defined by the reading of 260/280 ratio 
above 1.8 and the ratio of 260/230 for good nucleic acid is around 2.0-2.2 and 
usually higher than the corresponding 260/280 value. The integrity of the extracted 
DNA samples was determined by running a 1% agarose gel mixture with diluted 1X 
TBE from 10X TBE (Tris base 121.1 g, Boric acid 61.8 g, EDTA 7.4 g) in 0.5X TBE 
buffer for 90 minutes at 70 voltages. The gel was visualized under UV light in the 
UV Transilluminator (Uvitec, Cambridge, UK) following a gel electrophoresis. 
 
2.4 Epigenetic database built (gene and promoter) 
2.4.1 Candidate gene selection 
DNA methylation array was conducted using the Illumina Methylation 450k 
beadchip at the Wellcome Trust Clinical Research Facility generating data on 
485,000 CpG sites. Briefly, after bisulphite treatment, bisulphite-converted DNA was 
processed by using the Infinium HD Assay for methylation. The images for each 
arrays and genotypes were recorded automatically using GenomeStudio Analysis 
software (version 2011.1).  
The whole process of DNA methylation analysis can be separated in four steps and 
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the data were generated by using the RnBeads tool v 0.99.17 (Sparrow et al., 2016). 
First step was data loading followed by pre-processing. The next stage was 
normalisation using the beta mixture quantile dilation method (Teschendorff et al., 
2013). Finally, differential methylation between lean and obese pregnant women 
were assessed in gene bodies and promoters (by Dr Jon Manning). RnBeads (v77 
version) was used to analyses the different DNA methylation data and the regions of 
promoters are from 1.5kb upstream to 0.5kb downstream of the 5’-end (transcription 
start site). The false discovery rate (FDR) was used to select significant methylated 
genes/promoters.  
In total 288 genes were chosen from 27411 candidate genes identified as those that 
had a significant DNA methylation differences in the gene body after FDR 
adjustment between lean and obese (P<0.05). By excluding genes’ name as unknown 
(n=157) and the genes with a name but no information in PubMed/Web of Science/ 
Google Scholar (n=60), the total number of genes which could have relevant 
information (key words: obesity/BMI/overweight, pregnancy, human and placenta) 
in PubMed gene database were 71. Out of these 71 genes, 57 genes were excluded as 
they were not relevant to obesity or pregnancy, such as basic immune biology (n=7); 
cell interaction (n=23); hair (n=2); muscle calcium (n=1); sperm (n=5); gene location 
(n=2) etc. The final potential candidate genes were 14 in total (Figure 2).  
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2.4.2 Candidate promoter selection 
The total number of candidate differentially methylated promoters between obese 
and lean (P<0.05) were 362. By excluding the promoters with no information in 
PubMed/Web or Science/ Google Scholar (n=180), out of 180 there were 21 
promoters each have a ‘sibling’ promoter to share a same name but different 
positions. The total number of promoters which could be found with key words 
‘pregnancy’ and ‘obesity’ in PubMed gene database were 182. Out of these 182 
promoters, 19 promoters shared the same name and 142 promoters were excluded as 
they were not relevant to obese and pregnancy, such as basic immune biology (n=17); 
cell interaction (n=43); hair (n=6); muscle calcium (n=3); gene basic information 
(n=35) etc. The final potential candidate promoters were 40 in total, including 19 
promoters with the same name (Figure 3). 
 
Out of those candidate genes and promoters, three genes microRNA-411 (miR-411), 
fatty acid binding protein 1 (FABP1) and hydroxysteroid 17-beta dehydrogenase 4 
(HSD17B4) were chosen as our final target genes for further investigation. MiR-411 
has been found to be significantly down regulated in an experimental model of a 
diabetogenic-like environment (250 mg/dl glucose and 200 µg/µl advanced glycation 
end products (AGEs) with human serum albumin) using human umbilical vein cord 
endothelial cells (Zitman-Gal et al., 2014). However, Zitman-Gal’s study is limited 
as this was an experimental study mimicking the diabetic environment rather than 
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using samples from women with gestational diabetes. In another study using human 
placenta samples (mild preeclampsia (n=8), severe preeclampsia (n=15) and normal 
pregnant women (n=11)), a distinctive down-regulation of miR-411 (P=0.437 fold 
change) was demonstrated under preeclampsia (PE) conditions. Mild PE was defined 
as maternal systolic blood pressure of ≥140 mm Hg and/or diastolic blood pressure 
of ≥90 mm Hg on 2 occasions separated by 6 hours and significant proteinuria (≥300 
mg of protein in a 24-hour urine specimen or ≥1+ by dipstick) after 20 weeks of 
gestation. Severe PE was defined as either severe hypertension (systolic blood 
pressure of ≥160 mm Hg and/or diastolic blood pressure of ≥110 mm Hg on at least 2 
occasions 6 hours apart) plus mild proteinuria or mild hypertension plus severe 
proteinuria >2 g/24 hr or >2+ by dipstick). However, this study is limited by the 
small number of samples in each group (Zhu et al., 2009).  
 
FABP1, also known as liver FABP has been reported to bind or up-take long-chain 
fatty acid (LCFAs) in the cytosol during LCFA β-oxidation. LCFA β-oxidation is a 
long process whereby fatty acids are broken down to produce energy. As LCFA is an 
important mediator of dietary fat uptake, the authors suggested that FABP1 has a 
potential role in prevention of diet-induced obesity (Atshaves et al., 2010). FABP1 
was also suggested to play a vital role in hepatic lipid metabolism. In a study using a 
mouse model of nonalcoholic fatty liver disease (NAFLD) and human hepatocytes 
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without steatosis, a significant decrease of FABP1 gene expression was demonstrated 
in NAFLD (Guzmán et al., 2013). Rat recombinant L-FABP protein was used in a 
study which suggested FABP1 could influence glucose homeostasis by binding with 
glucose (high affinity for glucose, Kd =103.1±18.6 nM). The high concentration 
(20-30 mM) of glucose increased the interaction of FABP1 with peroxisome 
proliferator-activated receptors (PPARs) and it was suggested that this could 
consequently affect fat metabolism. A limitation is that this is an animal study 
(Hostetler et al., 2010). However, FABP1 deficient mice have been used in many 
studies aiming to understand the function FABP1. A few studies have shown an 
age-dependent weight gain (P<0.05, 4 g in male and female at age of 9 months) in 
both male and female FABP1 deficient mice. It was also shown that high fat diets 
could exacerbate (P<0.003, 1.8 fold change) the body weight in FABP1 knock-out 
female mice more than wild type female mice (Martin et al., 2006; Martin et al., 
2009; Atshaves et al., 2010). 
 
Mutation of HSD17B4 was found in Zellweger syndrome, a disorder of peroxisomal 
fatty acid β-oxidation, which results in D-bifunctional protein (DBP) deficiency, and 
with a phenotype of hypotonia and seizures in early life (Suzuki et al., 1997; van 
Grunsven et al., 1998; de Launoit and Adamski, 1999). In a recent study, different 
types of DBP deficiency and the link with HSD17B4 gene was analyzed. In a single 
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case report of a newborn with severe hypotonia and craniofacial dysmorphism, a 
N457Y mutation in the HSD17B4 gene was reported (Nascimento et al., 2015). High 
fat diet among female mice was demonstrated to induce gene expression of Hsd17b4 
in mice liver and help with increasing peroxisomal β -oxidation enzymes (Kozawa et 
al., 2011). Mulberry leaf was described involved in relieving dyslipidemia by 
upregulation the transport of long fatty acids in previous study (Doi, Kojima and 
Fujimoto, 2000). In a study using male Wistar rats (outbred albino rat, 5 weeks old, 
n=30), gene expression of Hsd17b4 in rats’ liver was increased in the group fed with 
mulberry leaf with high-fat diet, which indicates Hsd17b4 could also be involved in 











Figure 2. Identification of genes for validation. Total candidate genes were 
generated from 60 placenta samples. Selection of final candidate genes is basically 
based on the relevance of the gene to pregnancy, maternal disease, epigenetic 
changes and fat metabolism. 






Figure 3. Identification of promoters for validation. Total candidate genes were 
also generated from 60 placenta samples. Selection of potential promoters is 
basically based on the relevance of the gene to pregnancy, maternal disease, 
epigenetic changes and fat metabolism. The final candidate promoters were 
validated with the final genes we choose. 




2.5 DNA bisulfite conversion 
EZ DNA MethylationTM Kit was used for bisulfite conversion of DNA. Briefly,  
DNA samples (500 ng) were mixed with M-Dilution Buffer (5 µl) and water to 50 µl 
following by 15 minutes incubation at 37 ◦C. CT Conversion Reagent (100 µl) was 
added to the mixture for 16 hours incubation at 50 ◦C for 16 hours. M-Binding Buffer 
(400 µl) and samples were loaded into Zymo-SpinTM IC Colimn with collection tube. 
After four wash steps (according to the manufacturer’s handbook), M-Elution Buffer 
(10 µl) was added to elute the DNA. Followed with 30 µl RN-ase free water dilution 
for later PCR work. Samples were stored at -20 ◦C for further use. 
 
2.6 Primer validation 
Nine different assays: miR-411(n=2), HSD17B4 (n=3) and FABP1 (n=3), were tested 
to identify the best primers and temperatures to work with in the subsequent PCR. 
PCR primers were designed using PyroMark Assay Design Software 2.0 (Qiagen; 
https://www.qiagen.com). In detail, master mix (5µl), primer mix (forward and 
reverse primers, 0.4 µl), diluted converted test DNA (0.5 µl) and RN-ase free water 
were mixed to 10 µl. PCR was carried out for 45 cycles at four different temperatures 
50◦C, 53◦C, 56◦C and 60◦C, in which 50 ◦C was set according to the manufacturer’s 
handbook with recommended temperature for assays to work in PCR and adjusted in 
following step by different gradations (53◦C, 56◦C and 60◦C) to find out the best 
temperature for PCR to work. Water control was used as negative control. Agarose 
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gel (1%) was ran to test the quality of different assays with PCR samples (10 µl) and 
6 X loading dye (2 µl). 
 
2.7 Pyrosequencing 
Total volume for PCR were increased to 30 µl, with master mix (15 µl), primer mix 
(forward and reverse primers, 1.2 µl), diluted conversed test DNA (2 µl) and RN-ase 
free water (11.8 µl) by using the AmpliTaq Gold 360 kit (Applied Biosystems, 
Warrington, UK). Only 5 µl PCR samples were used for gel image, the rest samples 
(25 µl) were prepared for pyrosequencing. Pyrosequencing was performed according 
to the manufacturer’s instructions by using PyroMark Gold Q24 reagents on a 
PyroMark Q24 Pyrosequencer (Qiagen). Data were analysed using PyroMark Q24 







   Table 2. Primers for pyrosequencing. 
  





 Forward primer TTTAGGTTTTTATAGTGGGAAGGTATT 









 Forward primer AATGTTTGGGGTTGTGGGATT 










 Forward primer TAAGGAAGAAATTATGGGTTGTTG 







2.8 RNA extraction from placenta tissues 
Human placenta samples were collected from ERTBB (The Edinburgh Reproductive 
Tissue Bio Bank) as detailed in Mina et al (2015b). We applied the Qiagen 
miRNeasy Mini kit (Qiagen, Crawley, West Sussex, UK) protocol, detailed as 
follows. Approximately 30 mg tissue were cut and mixed with 700 µl QIAzol Lysis 
Reagent in Magna lyser green beads tubes (Roche, Mannheim, Germany), and 
homogenized using Qiagen Tissue Lyser for 50 seconds x 25 Hz for 5 minutes and 
incubated at room temperature for 5 minutes. The lysates were subsequently mixed 
with 140 µl chloroform and vortexed for 15 seconds. The mixture was incubated at 
room temperature for 3 minutes, followed by centrifugation at 12,000 xg at 4 ◦C for 
15 minutes. Subsequently the upper aqueous layer (containing RNA) of the samples 
was transferred to a new tube with 525 µl ethanol added and the mixture was 
transferred to an RNeasy Mini spin column tube. Three wash steps were followed 
and the remainder of the extraction steps were as per the manufacturer’s protocol. 
 
2.8.1 RNA quantification and verification of integrity 
The concentrations of the extracted RNAs were assessed by means of Nanodrop 
(Thermo-Scientific, Loughborough, UK) and the initial quality control was 
determined by 260/280 ratio. Samples with total RNA concentration ≥200 µl were 
deemed suitable for the subsequent verification stage. The integrity of RNA was then 
verified using Agilent 6000 Nano kit (Agilent Technologies, Berkshire, UK), which 
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were processed on the Agilent 2100 Bioanalyzer (Agilent Technologies) as per the 
manufacturer’s protocol. The ribosomal ratio 260/280 results > 2.00 and clear bands 
in the gel image were used as the cut-off values for excellent RNA integrity. 
 
2.9 RT-qPCR 
2.9.1 RT-qPCR for FABP1 
DNase treatment was carried out before RT using DNase treatment kit (Promega, 
Southampton, UK). Briefly, a mixture of RQ1 reaction buffer 10X (1 µl), RQ1 
RNase-Free DNase (1 µl) and 7 µl RNA samples was incubated at 37 ºC for 30 
minutes. RQ1 RNase stop solution (1 µl) was added with another incubation at 65 ºC 
for 10 minutes. Total volume of 20 µl mixture was used for per RT reaction per 
sample (n=9), including treated RNA mixture (10 µl), 100mM dNTPs with dTTP 
(0.8 µl), Reverse Transcriptase (50 U/µl, 1 µl), 10 X Reverse Transcription Buffer (2 
µl), Nuclease-free water (3.2 µl), primers 10 X (2 µl), according to ABI High 
Capacity Reverse Transcription Kit (Applied Biosystems, Paisley, UK) protocol. 
Standard curve was generated with Nuclease-free water for 1:8 dilutions. Mixtures 
were hold at 30 ºC for 16 minutes, followed 30 ºC for 42 minutes and 5 ºC for 85 
minutes, with a final hold at 4 ºC by using Prime RT machine. 
Total volume of 10 µl mixture was used in qPCR per well, with PerfeCTa® QRTPCR 
Fastmix® II (5 µl, Quanta, Bioscience, Leicestershire, UK), three different probes 
(0.1 µl each, FABP1, TBP, YWHAZ), 0.2 µl forward primer and 0.2 µl reverse 
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primer (FABP1, TBP, YWHAZ each), Nuclease-free water (2.5 µl) and 2 µl diluted 
cDNA (1:4). One Nuclease-free water and housekeeping gene were performed in per 
reaction. All samples were done in triplicates. Plate was hold at 95 ºC for 10 minutes, 
followed 40 cycles at 94 ºC for 10 seconds and 68 ºC for 60 seconds by using Lighter 
Cycler 480 system (Roche, London, UK). 
 
2.9.2 RT-qPCR for miR-411 
Total volume of 15 µl mixture was used for per RT reaction per sample (n=46), 
including 100mM dNTPs with dTTP (0.15 µl), MultiScribeTM Reverse Transcriptase, 
50 U/µl (1 µl), 10 X Reverse Transcription Buffer (1.5 µl), RN-ase Inhibtor, 20 U/µl 
(0.19 µl), Nuclease-free water (4.16 µl), U6 primers (3 µl), miR-411 primers (3 µl) 
and diluted RNA samples (1 ng, 5 µl), by following the protocol of Taqman miRNA 
reverse transcription kit (Applied Biosystems, UK). Standard curve was made by 
Nuclease-free water for 1:8 dilutions. Mixtures were hold at 16 ºC for 30 minutes, 
followed 42 ºC for 30 minutes and 85 ºC for 5 minutes, with a final hold at 4 ºC by 
using Prime RT machine. 
Total volume of 10 µl mixture was used in qPCR per well, with PerfeCTa® QRTPCR 
Fastmix® II (5 µl, Quanta, Bioscience, Leicestershire, UK), 20X miR-411 assay 
(ThermoFisher scientic, UK), 20X U6 assay (ThermoFisher scientic, UK, ID: 
001973), Nuclease-free water (2.5 µl) and 2 µl diluted cDNA (1:5). One 
Nuclease-free water and one mixture without MultiScribeTM Reverse Transcriptase 
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were used as negative control. All samples were done in triplicates. Plate was hold at 
95 ºC for 10 minutes, followed 40 cycles at 95 ºC for 15 seconds and 60 ºC for 60 
seconds by using Lighter Cycler 480 (Roche, London, UK). Two miR-411 assays: 
miR-411-5p (ID: 001610) and miR-411-3p (ID: 00002238) were tested in this study, 
details see Table 3. MiR-411-5p and miR-411-3p arise from 5’ arm and 3’ arm of the 
miR-411 hairpin respectively, and it has been demonstrated in a previous study that 
miRNAs derived from different arms show different mRNA levels and functions 
(Guo et al., 2015; Kuo et al., 2015). Thus we chose to test both of these two miRNAs 





















Table 3. Assays used in qPCR reaction in this study. 
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2.10 Data analysis 
Data generated from qPCR were analyzed by SPSS version 22 (IBM, New York, 
USA). Data normal distribution was tested by Shapiro-Wilk’s test (P>0.5 as 
significant), Q-Q Plot and visual histograms. Outliers (>3SD from mean) were 
excluded. We used ln-transformation to normalize data that were not normally 
distributed but this did not improve the distribution. Therefore parametric statistics 
were used for normally distributed data and non-parametric statistics for 
non-normally distributed data. T-test (unpaired) was used to compare the differences 
in DNA methylation data between obese and lean groups. Mann-Whitney U test was 
used to compare gene expression data between groups. Pearson’s correlation was 
used to test correlations of DNA methylation data with maternal BMI, smoking status, 
fetal birth weight and infant BMI etc. and Spearman correlation was used to test 
correlations of gene expression data with maternal BMI, smoking status, fetal birth 
weight and infant BMI etc. Regression analyses were performed with mRNA levels 
as independent variables and different maternal and fetal status (such as maternal 
smoking status and fetal sex) as dependent variables. Histograms of residuals were 
tested as normal distribution before performing regression analysis. P<0.05 was 






3 Results   
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3.1 The demographics of participants  
Characteristics of the participants from which the placental samples were used in this 
study are shown in Table 4. There were significant differences in maternal BMI, age 
and Standard Deviation Score of birth weight (sds_bw) between lean and obese 
group. Maternal BMI was significantly higher in obese group than lean group, while 
maternal age was significantly higher in lean group compared with obese group. 


















Table 4. Maternal and fetal demographics. SO, severely obese; S.D., standard deviation; 
BMI, body mass index; SDS_bw, Standard Deviation Score of birth weight (British 
standard), this is birth weight index adjusted for their gestational age and sex; PI, 
Ponderal index in kg/m3, this is BMI version for infants as infants tend to have similar 
length of leg and torso, unlike adults; SDS_BMI, Standard Deviation Score of birth BMI 
(British standard), there is no national standard for PI. “a” represents P value generated 




3.2 DNA quality and quantity 
The quality of DNA samples was measured by Nanodrop, with concentration at 400 
~ 500 µl, 260/280 at 2.0, 260/230 at 1.8. The integrity of DNA was measured by 1% 














Figure 4. An example of gel image of DNA samples. From left to right sample 
(no.): 645, 572, 563, 628, 575, 625, 634, 631, 411, 403, 447, 442, 626, 646.  
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3.3 Primer test 
Different primers for each gene were tested before pyrosequencing. Primers were 
adjusted at different temperature while running PCR, gel image was captured. In 
Figure 5. Examples were given for each gene of primer test. From the image we can 
see, miR-411 assay showed a brightest band at 50 ºC (Fig.5 A), while a brightest 
band was shown at 58 ºC for FABP1 assay (Fig.5 B), and HSD17B4 assay presented 




























Figure 5. PCR gel images of test primers in different temperature. A. shows a clearer 
band at 50 ºC; B. shows a brighter band at 53 ºC, and in C. a clean band can be 
observed at 58 ºC. W means water control. 
A	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 B	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 C	
	 58	
 
3.4 Pyrosequencing for DNA methylation and data analysis 
There are three different results from pyrosequencing, ‘pass’ (blue), ‘check’ (yellow) 
and ‘fail’ (red), both ‘check’ and ‘fail’ results were repeated in this experiment by 
improving the quality of DNA samples. Water controls showed as ‘fail’ status means 















           
(A) 










Figure 6. Examples of pyrosequencing results. (A) A passed (blue) result with 80% 
DNA methylation and no additional warning. (B) A need to be checked (yellow) result 
with 75% DNA methylation with uncertain bisulfite conversion at position 15. (C) A 
failed (red) result with no data can be analyzed. 
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Differences in DNA methylation between the three genes: miR-411, FABP1 and 
HSD17B4 are shown in Table 5. DNA methylation of both FABP1 and miR-411 was 
significantly higher in obese compared with lean but there were no differences in 












Table 5. Differences between obese and lean in placental DNA methylation in 
three different genes: HSD17B4, miR-411 and FABP1. 
“a” represents P value generated using t-test (significant <0.05). 
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3.5 RT-qPCR data analysis with DNA methylation results 
3.5.1 miR-411-5p and miR-411-3p gene expression in lean and obese placenta 
overview 
The miR-411-5p gene expression in lean and obese placentas is shown in Fig.7 (a), 
and miR-411-3p is shown in Fig.7 (b). No differences were observed in either 
miR-411-5p or miR-411-3p mRNA levels between lean and obese groups. 






Figure 7. Scatter plot shows miR-411-5p/3p gene expression in lean/obese placenta. 
(a) miR-411-5p gene expression in lean (n=22) and obese (n=24) placentas and (b) 
miR-411-3p gene expression in lean (n=21) and obese (n=24) placentas. The 
horizontal line is presented as median. 
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3.5.1.1 miR-411-5p and miR-411-3p gene expression vs maternal smoking status 
The mRNA levels of miR-411-5p/3p were compared with maternal smoking status 
(Figure 8). Gene expression of miR-411-5p in placentas from smoking group was 
higher in samples collected from ex-smokers and significantly higher than samples 
from non-smoking women (P=0.03, see Fig.8 (a)). A similar pattern was observed in 
miR-411-3p, though there were no statistical differences (Fig.8 (b)). 
Further investigation of gene expression differences between lean and obese 
placentas vs maternal smoking status are shown in Fig.8 (c) & (d). We can see that 
obese placentas in smoking group showed the highest mRNA levels of miR-411-5p 
(Fig.8 (c)), which was significantly higher than non-smoking obese placentas 
(P=0.04) and ex-smoker obese placentas (P=0.03), but there were no differences 
comparing lean placentas (P>0.05). The analysis of miR-411-3p also showed a 
similar pattern but there were no significant differences (Fig.8 (d)). The mRNA 
levels in obese ex-smoker were higher than obese non-smoking in miR-411-5p group, 
whereas the mRNA levels in obese ex-smoker was lower than obese non-smoking in 








Figure 8. Scatter plot shows miR-411-5p/3p gene expression vs smoking in lean and 
obese placenta. (a) Overview of miR-411-5p gene expression in placentas vs maternal 
smoking status (non-smoking=23, ex-smoker=19, smoking=4) and (b) Overview of 
miR-411-3p gene expression in placentas vs maternal smoking status 
(non-smoking=23, ex-smoker=18, smoking=4). (c) miR-411-5p gene expression in 
lean and obese placentas vs maternal smoking status respectively. (d) miR-411-3p 
gene expression in lean and obese placentas vs maternal smoking status respectively. 
The horizontal line is presented as median. 
Note: P<0.05. l-ns=lean non-smoking, l-es=lean ex-smoker, l-s=lean smoking, 
o-ns=obese non-smoking, o-es=obese ex-smoker, o-s=obese smoking. L-s group 
(n=0). 
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3.5.1.2 miR-411-5p and miR-411-3p gene expression vs maternal age and BMI 
The correlation of miR-411-5p/3p gene expression with maternal age and BMI was 
tested. There was a negative correlation between miR-411-5p mRNA levels and 
maternal age in obese placentas (r=-0.42, P=0.05), but no correlation was seen in 
lean placentas between obese placentas (Fig.9 (a,b)). There was no correlation of 
miR-411-3p mRNA levels with maternal age in either lean or obese groups (Fig.9 
(c.d)). There was no correlation of miR-411-5p gene expression with maternal BMI, 












Figure 9. Correlation between miR-411-5p/3p gene expression and maternal age/BMI. 
(a) miR-411-5p gene expression in obese placentas vs maternal age. (b) miR-411-5p 
gene expression in lean placentas vs maternal age. (c) miR-411-3p gene expression in 
obese placentas vs maternal age. (d) miR-411-3p gene expression in lean placentas vs 
maternal age. (e) miR-411-5p gene expression in obese placentas vs maternal BMI. (f) 
miR-411-5p gene expression in lean placentas vs maternal BMI. (g) miR-411-3p gene 
expression in obese placentas vs maternal BMI. (h) miR-411-3p gene expression in 
lean placentas vs maternal BMI.  
Note: Spearman correlation indexes “r” and “P” (significant <0.05) are shown in the 
figure. The straight line represents the best-fit line generated by liner regression 
analysis. 
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3.5.1.3 miR-411-5p and miR-411-3p gene expression vs baby sex 
Female lean placenta showed the highest mRNA levels in both miR-411-5p and 
miR-411-3p. The gene expression of miR-411-5p in female lean placenta was 
significantly higher than male lean placenta group (P=0.04). MiR-411-5p gene 
expression was also higher in male obese placenta than male lean placenta but this 
difference was not statistically significant (Fig.10 (a)). Similar results also can be 
seen in miR-411-3p, the mRNA level was noticeably higher in female lean placenta 
than male lean placenta group (P=0.004). We also found miR-411-3p gene 
expression in male obese group was significantly higher than male lean group 
(P=0.05). Moreover, miR-411-3p gene expression in female obese group was also 










Figure 10. Scatter plot shows miR-411-5p/3p gene expression vs baby sex in lean and 
obese placenta. (a) miR-411-5p gene expression in lean and obese placentas vs baby 
sex. (b) miR-411-3p gene expression in lean and obese placentas vs baby sex. 
Note: P<0.05;  P<0.005. lm=lean male, lf=lean female, om=obese male, 
of=obese female. 
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3.5.1.4 miR-411-5p and miR-411-3p gene expression vs birth weight and infant 
BMI. 
We found there were no correlations of infant birth weight with miR-411-5p and 
miR-411-3p gene expression in lean and obese placentas (Fig.11 (a,b,c,d)). We found 
a strong positive correlation between infant BMI and the mRNA levels of 
miR-411-5p in lean group (r=0.636, P<0.005, Fig.11 (f)), and similar results were 
also seen in miR-411-3p (r=0.661, P<0.005, Fig.11 (h)). However, no correlation of 


















Figure 11. Correlation between miR-411-5p/3p gene expression and infant birth 
weight/BMI. (a) miR-411-5p gene expression in obese placentas vs birth weight. (b) 
miR-411-5p gene expression in lean placentas vs birth weight. (c) miR-411-3p gene 
expression in obese placentas vs birth weight. (d) miR-411-3p gene expression in lean 
placentas vs birth weight. (e) miR-411-5p gene expression in obese placentas vs infant 
BMI. (f) miR-411-5p gene expression in lean placentas vs infant BMI. (g) miR-411-3p 
gene expression in obese placentas vs infant BMI. (h) miR-411-3p gene expression in 
lean placentas vs infant BMI.  
Note: Spearman correlation indexes “r” and “P” (significant <0.05) are shown in the 
figure. The straight line represents the best-fit line generated by liner regression 
analysis. 
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3.5.1.5 miR-411-5p and miR-411-3p gene expression vs PI and sds_BMI/bw 
To further investigate the correlation of miR-411-5p/3p gene expression with infant 
birth weight and BMI, we also analyzed PI (ponderal index in kg/m3, a BMI version 
for infants as infants tend to have similar length of leg and torso, unlike adults), 
sds-bw (Standard Deviation Score of birth weight (British standard), birth weight 
index adjusted for their gestational age and sex) and sds_BMI (Standard Deviation 
Score of birth BMI (British standard)). Although there was no correlation of PI with 
miR-411-5p/3p gene expression in obese placentas (Fig.12 (a,c)), there was a 
significant positive correlation of PI with miR-411-5p/3p gene expression in lean 
placentas (5p: r=0.523, 3p: r=0.541; P<0.05, Fig.12 (b,d)). We also found a 
significantly positive correlation of sds_BMI with mRNA levels of miR-411-5p/3p in 
lean group (Fig.12 (f,h)), whereas no correlation was seen in obese group (Fig.12 
(e,g)). No correlation was shown between sds_bw and miR-411-5p/3p gene 
expression in both groups (Fig.12 (i,j,k,l)). Sds_bw in lean placentas tended to be 



















Figure 12. Correlation between miR-411-5p/3p gene expression and 
PI/sds_bw/sds_BMI. (a) miR-411-5p gene expression in obese placentas vs PI. (b) 
miR-411-5p gene expression in lean placentas vs PI. (c) miR-411-3p gene expression 
in obese placentas vs PI. (d) miR-411-3p gene expression in lean placentas vs PI. (e) 
miR-411-5p gene expression in obese placentas vs sds_BMI. (f) miR-411-5p gene 
expression in lean placentas vs sds_BMI. (g) miR-411-3p gene expression in obese 
placentas vs sds_BMI. (h) miR-411-3p gene expression in lean placentas vs sds_BMI. 
(i) miR-411-5p gene expression in obese placentas vs sds_bw. (j) miR-411-5p gene 
expression in lean placentas vs sds_bw. (k) miR-411-3p gene expression in obese 
placentas vs sds_bw. (l) miR-411-3p gene expression in lean placentas vs sds_bw. 
Note: Spearman correlation indexes “r” and “P” (significant <0.05) are shown in the 




3.5.1.6 Regression of miR-411-5p and miR-411-3p gene expression vs maternal 
smoking status and baby sex 
Multiple linear regression analyses were performed to examine whether the 
relationship between miR-411-5p/3p gene expressions and baby sex was independent 
of maternal smoking, see Table 6. Analyses were conducted separately for the lean 
and obese groups. In the lean group, miR-411-5p gene expressions was higher in 
female placentas than in male placentas, independently of maternal smoking (Table 
6a). In contrast, in obese (Table 6b), there was no association of miR-411-5p gene 
expression with fetal sex, but smoking was associated with this gene. MiR-411-5p 
gene expressions was higher in smokers than ex-smokers and non-smoking in obese 
placentas. There were similar findings for miR-411-3p in lean (Table 6c) and a 
similar pattern in obese (Table 6d), though the latter failed to reach statistical 





























Table 6. Multiple linear regression analysis. (a) regression between miR-411-5p_lean 
gene expression and maternal smoking status/fetal sex. (b) regression between 
miR-411-5p_obese gene expression and maternal smoking status/fetal sex. (c) 
regression between miR-411-3p_lean gene expression and maternal smoking 
status/fetal sex. (d) regression between miR-411-3p_obese gene expression and 
maternal smoking status/fetal sex.  
Note: P<0.05 as significant. a: independent variable (maternal smoking status and 
fetal sex). 
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3.5.2 miR-411 DNA methylation in lean and obese placenta vs maternal smoking 
status 
There were no substantial differences in miR-411 DNA methylation between 
smoking, ex-smoker and non-smoking groups (Fig.13 (a)). 
In detailed analysis between lean and obese groups with different smoking status is 
shown in Fig.13 (b). The mean DNA methylation percentage of miR-411 in obese 
non-smoking group was higher than the ex-smoker in the same group but not 
significant different (P>0.05), whereas the mean DNA methylation percentage of 
miR-411 in obese non-smoking group was significantly higher compared with lean 










Figure 13. Bar chat shows miR-411 DNA methylation vs smoking in lean and 
obese placenta. (a) Overview of miR-411 DNA methylation in all placentas 
samples vs maternal smoking status (non-smoking=30, ex-smoker=23, smoking=7) 
and (b) Overview of miR-411 DNA methylation in lean and obese placentas 
respectively vs maternal smoking status. Data are presented as mean value of 
percentage. 
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3.5.2.1 miR-411 DNA methylation in lean and obese placenta vs maternal age 
We found there was no correlation of miR-411 DNA methylation with maternal age 










Figure 14. Correlation between miR-411 DNA methylation and maternal age. (a) 
miR-411 DNA methylation in obese placentas(n=31) vs maternal age. (b) miR-411 
DNA methylation in lean placentas(n=29) vs maternal age.  
Note: Pearson correlation indexes “r” and “P” (significant <0.05) are shown in the 




3.5.2.2 miR-411 DNA methylation in lean and obese placentas vs baby sex 
The percentage of miR-411 DNA methylation in male baby obese group showed the 
highest level among all samples. In detail, miR-411 DNA methylation was 
significantly higher in male obese group than male lean group (P<0.05). In female 
group, female baby in obese group also showed higher DNA methylation than female 
lean group, but no different. The DNA methylation in male infant obese group was 


















Figure 15. Bar chat showing overview of miR-411 DNA methylation in lean and 
obese placentas respectively vs baby sex. (male obese=14, male lean=14, female 
obese=17, female lean=15). Data are presented as mean value of percentage. 
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3.5.2.3 miR-411 DNA methylation in lean and obese placenta vs birthweight, 
infant BMI and PI/sds_bw/sds_BMI 
No correlation was detected between miR-411 DNA methylation with infant birth 
weight, BMI, sds_bw and sds_BMI in both lean and obese placentas. There was a 
significant negative correlation between miR-411 DNA methylation with PI in obese 





















Figure 16. Correlation between miR-411 DNA methylation and infant 
bw/BMI/PI/sds_bw/sds_BMI. (a) miR-411 DNA methylation in obese placentas vs 
bw. (b) miR-411 DNA methylation in lean placentas vs bw. (c) miR-411 DNA 
methylation in obese placentas vs sds_BMI. (d) miR-411 DNA methylation in lean 
placentas vs sds_BMI. (e) miR-411 DNA methylation in obese placentas vs sds_bw. 
(f) miR-411 DNA methylation in lean placentas vs sds_bw. (g) miR-411 DNA 
methylation in obese placentas vs infant BMI. (h) miR-411 DNA methylation in lean 
placentas vs infant BMI. (i) miR-411 DNA methylation in obese placentas vs PI. (j) 
miR-411 DNA methylation in lean placentas vs PI.  
Note: Pearson correlation indexes “r” and “P” (significant <0.05) are shown in the 




3.5.3 miR-411 DNA methylation vs gene expression in lean and obese placenta  
The correlation of miR-411 DNA methylation and gene expression was tested in both 







Figure 17. Correlation between miR-411 DNA methylation and gene expression. (a) 
miR-411 DNA methylation(n=25) vs miR-411-5p gene expression(n=24) in obese 
placentas. (b) miR-411 DNA methylation(n=22) vs miR-411-5p gene 
expression(n=22) in lean placentas. (c) miR-411 DNA methylation(n=25) vs 
miR-411-3p gene expression(n=24) in obese placentas. (d) miR-411 DNA 
methylation(n=22) vs miR-411-3p gene expression(n=21) in lean placentas.  
Note: Spearman correlation indexes “r” and “P” (significant <0.05) are shown in the 





3.5.4 FABP1 gene expression in lean and obese placentas 
The standard curve of gene FABP1 and housekeeping gene TBP and YWHAZ were 
shown in Figure 18. High efficiency PCR can be observed in housekeeping gene 
TBP and YWHAZ (slope<-3.32, R2 ≥0.99, Fig. 18(a,b)), whereas no results were 




















Figure 18. Standard curve of gene FABP1 and housekeeping gene TBP and 
YWHAZ. (a) standard curve of housekeeping gene TBP. (b) standard curve of 











In our study, we demonstrated differences in DNA methylation and gene mRNA 
levels between placentas collected from lean and obese women. However, there were 
no correlations between DNA methylation and mRNA levels. It has been suggested 
that epigenetic mechanisms such as DNA methylation and microRNAs may underpin 
the DOHaD hypothesis (Wadhwa et al., 2009). While investigators have started to 
investigate this, such as whether there is an epigenetic effect of maternal smoking on 
offspring brain development; and whether epigenetic gene modifications have an 
effect on human longevity (Toledo-Rodriguez et al., 2010; Zucchi et al., 2013), only 
few studies have been carried out to examine the influence of maternal obesity on 
epigenetic processes in the offspring and their later life (Swanson et al., 2009; 
Godfrey et al., 2016).  
 
Following examination of differences between DNA methylation between placentas 
collected from obese and lean placentas by array, we identified three genes, miR-411, 
FABP1 and HSD17B4 for validation. These were selected as previous studies had 
suggested they could all be potentially relevant to fat metabolism and maternal 
pregnancy complications, though the function of these genes in the placenta is 
unknown (Atshaves et al., 2010; Kozawa et al., 2011; Zitman-Gal et al., 2014). 
 
The family of FABPs were demonstrated as fatty acid transporters involved in fat 
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metabolism in a previous study (Thumser and Storch, 2000). In our study, although 
we found significantly higher FABP1 DNA methylation in obese than lean placentas, 
we did not detect the gene expression FABP1 in placenta samples. The reason for this 
may be due to tissue specific gene expression, FABP1 was mainly found in liver 
tissue (Guzmán et al., 2013), and we examined placental tissue in this study. 
 
MiR-411 mRNA levels measured in human umbilical vein cord endothelial cells 
have been demonstrated to decrease under diabetic conditions (Zitman-Gal et al., 
2014). A distinctive down-regulation of miR-411 mRNA levels was also reported in 
placentas collected from women with preeclampsia compared to placentas from 
women with uncomplicated pregnancies (Zhu et al., 2009). In our study, we found 
higher DNA methylation in obese placenta than lean samples, but no differences of 
mRNA levels in those two groups. In order to understand the reason why there are no 
differences of miR-411 gene expression between lean and obese placentas, we 
further compared maternal smoking status and baby sex and infant BMI.  
 
Smoking, one of the common adverse environmental exposures during pregnancy, 
has previously been shown to be associated with altered DNA methylation induced 
gene expression changes in whole blood samples from offspring (Markunas et al., 
2014; Richmond et al., 2015). Smoking during pregnancy is known to have adverse 
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outcomes on fetal health and later life. For example, preterm birth and low birth 
weight are strongly associated with maternal smoking (Ng and Zelikoff, 2007). In 
our study, the miR-411 mRNA levels in the placentas collected from mothers in the 
smoking group were significantly higher than in those collected from non-smokers 
and ex-smokers. This result is consistent with a previous study that found 623 genes 
were differentially expressed between smokers and non-smokers in placental tissue 
(Suter et al., 2011). Another study also demonstrated the influence of smoking on a 
specific gene IGF2 mRNA levels (Hoyo et al., 2012). However, we did not detect 
DNA methylation changes of miR-411. This is in accord with one previous study that 
mentioned 1,024 placental CpGs were found to be differently methylated between 
smokers and non-smokers, but only 38 CpG sites had more than 10 % differences in 
methylation levels (Suter et al., 2011). This brings us to question the extent to which 
environmental exposures impact on DNA methylation alterations and whether small 
methylation changes can have a functional impact. 
 
We also demonstrated highest miR-411 DNA methylation in placentas collected from 
male infants whereas the highest miR-411 mRNA levels were in placentas from 
females. While this finding needs replicating in a larger sample size, it suggests there 
may be sex-specific differences in DNA methylation and gene expression. Baby sex 
was found to be an independent factor affecting the miR-411 gene expression in lean 
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placentas, while maternal smoking factor was found to have an independent impact 
on gene expression in obese placentas. It is interesting that we found a positive 
correlation of infant BMI with miR-411 mRNA levels in the lean group, whereas no 
correlations between infant BMI and miR-411 levels were found in the obese group. 
This new finding suggests that miR-411 might be potentially involved in fetal fat 
metabolism, especially from lean pregnant women. We also found that fetal sex was 
independently associated with miR-411 gene expression in the lean group, and 
maternal smoking status was independently associated with miR-411 gene 
expression in the obese group, indicating the possibility that various maternal and 
fetal factors predict gene expressions. However, these regression models only 
predicted less than 50% of the variation (R2<0.5) of miR-411 gene expression by 
different maternal smoking status and fetal sex. As we had small sample sizes in each 
group in these regression models, these findings need to be replicated in a larger 
sample size. 
 
Our study shows DNA methylation differences between lean and obese placentas in 
both FABP1 and miR-411, but we were unable to detect differences in DNA 
methylation of HSD17B4 between groups. This is the first time that DNA 
methylation of HSD17B4 has been analyzed using human placenta samples. We 
found the DNA methylation levels of HSD17B4 was 74.13% in obese placenta and 
73.17% in lean placenta. HSD17B4 is commonly known to be involved in the fatty 
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acid β-oxidation metabolism pathway (van Grunsven et al., 1998), and mutation of 
this gene has been found to cause DBP deficiency (Zellweger syndrome), with 
symptoms including hypotonia and seizures (Suzuki et al., 1997). In one human 
breast tumour study, DNA methylation and mRNA expression of HSD17B4 were 
found to have an inverse association in human HER-2/neu-positive breast cancer 
using 143 tumour samples (Fiegl et al., 2006). In our study we did not find 
differences of HSD17B4 methylation between lean and obese placentas. The reason 
is unknown, but may be because different tissue types have differing DNA 
methylation changes or there may be differences in other DNA methylation regions 
that we did not study. 
 
DNA methylation changes can be cell and tissue specific (Eckhardt et al., 2006). In 
one study Novakovic et al (2013) analyzed DNA methylation changes in the AhRR 
gene according to maternal smoking status using placenta samples, umbilical cord 
blood and buccal cells. They found lower AhRR DNA methylation level in cord 
blood, whereas no detectable methylation level changes in buccal cells and placenta 
tissues (Novakovic et al., 2014). This study indicates that the influences of smoking 
during pregnancy can be cell and tissue specific. This is relevant to our study, as 
although FABP1 is a gene mainly found in liver, due to maternal smoking exposure 
we could observe its DNA methylation changes in placenta tissues with no detectable 
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mRNA levels. As FABP1 is a protein coding gene, it might be possible there are 
different protein expressions of FABP1 in lean and obese placenta samples. 
 
In a previous study, it was demonstrated that DNA methylation could turn active 
genes to silenced genes (Weber et al., 2007). This would mean that with higher DNA 
methylation levels then lower gene mRNA levels would be observed. The reason 
why we were unable to find any correlation of DNA methylation changes with gene 
expressions might due to tissue specific gene expression and maternal smoking 
environment. It might also be because the DNA methylation changes observed in this 
study were less than 10%, and how much change in DNA is needed to induce 
functional outcomes is still unclear. Moreover, these changes in DNA methylation 
and gene expressions also indicate that the placenta may play a protective role on 
fetal health from maternal different environment exposures. Also we would need to 
do functional studies to see if DNA methylation does regulate the expression of these 




Strengths and limitations  
The main strength of our study is the well-defined cohort with detailed information 
about the pregnant women and the fetus. We included placenta samples with a 
significantly different maternal BMI between lean and obese groups, and excluded 
GDM, PE and preterm birth samples. In our study, we analyzed genes and promoters 
potentially relevant to fat metabolism and maternal complications, and DNA 
methylation of HSD17B4 was analyzed for the first time in both lean and obese 
placentas. We also focused on the changes in these gene and promoters with different 
maternal and fetal status (e.g: maternal smoking status, maternal BMI, baby sex and 
fetal birthweight etc.), as this has not been examined before. 
 
One limitation in this study is that we did not have smoking samples included in lean 
group for miR-411 mRNA levels analysis. It would be interesting to replicate our 
findings in a further study with a larger number of samples to compare the changes 
of miR-411 mRNA levels between lean smoker and obese smoker placentas. Another 
limitation is that we did not have human liver samples collected in this study. It 
would be good to examine the mRNA levels of FABP1 in liver tissue, to determine if 
the expression could be found in liver tissue but not in placentas, indicating the 
possibility of tissue specific gene expression. Larger sample sizes are needed to 
replicate the finding of fetal sex and maternal smoking status with miR-411 gene 
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expression and DNA methylation. Moreover, it is still not clear whether the DNA 
methylation changes only happening in the maternal side or the fetal side of the 
placenta will have the same methylation patterns and our study is limited as we had 
full thickness placental biopsies. Also, it is not known if the alterations in DNA 
methylation could be persistent throughout the adult life. Further work could focus 
on the epigenetic correlation between maternal and fetal and the DNA methylation 
changes in fetus and adulthood.  
 
In conclusion, we observed DNA methylation changes between lean and obese 
placentas in both FABP1 and miR-411 genes, and the DNA methylation level was 
significantly higher in obese group than lean group in both of these genes. We also 
demonstrated the association of maternal smoking status, baby sex and infant BMI 
with miR-411 mRNA levels. Further work is needed to replicate our findings and to 
determine whether these changes are linked with any longer term outcomes on 
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